UBS Group assumed coverage on shares of EXACT Sciences (NASDAQ:EXAS) in a research report sent to investors on Tuesday, 99wallstreet.com reports. The brokerage issued a buy rating and a $100.00 target price on the medical research company’s stock.

Several other brokerages also recently weighed in on EXAS. BidaskClub downgraded EXACT Sciences from a hold rating to a sell rating in a report on Friday, August 10th. Leerink Swann reiterated an outperform rating and issued a $76.00 price target (up from $67.00) on shares of EXACT Sciences in a report on Wednesday, July 18th. Jefferies Financial Group cut their price target on EXACT Sciences from $60.00 to $57.00 and set a buy rating for the company in a report on Thursday, August 2nd. Robert W. Baird boosted their price target on EXACT Sciences from $65.00 to $74.00 and gave the company an outperform rating in a report on Thursday, August 23rd. Finally, Bank of America cut their price target on EXACT Sciences from $75.00 to $68.00 and set a buy rating for the company in a report on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $83.25.

EXAS stock opened at $67.22 on Tuesday. EXACT Sciences has a 1 year low of $37.36 and a 1 year high of $81.22. The company has a debt-to-equity ratio of 0.87, a quick ratio of 15.37 and a current ratio of 15.79. The company has a market capitalization of $9.69 billion, a P/E ratio of -69.26 and a beta of 0.98.

EXACT Sciences (NASDAQ:EXAS) last posted its earnings results on Wednesday, August 1st. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. The firm had revenue of $102.89 million for the quarter, compared to analyst estimates of $104.40 million. EXACT Sciences had a negative return on equity of 20.10% and a negative net margin of 35.24%. EXACT Sciences’s revenue was up 78.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.27) EPS. Analysts expect that EXACT Sciences will post -1.41 earnings per share for the current year.

In other news, insider D Scott Coward sold 2,190 shares of the company’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $79.51, for a total transaction of $174,126.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Graham Peter Lidgard sold 58,000 shares of the company’s stock in a transaction on Monday, October 8th. The stock was sold at an average price of $69.36, for a total value of $4,022,880.00. Following the sale, the insider now owns 204,684 shares of the company’s stock, valued at $14,196,882.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 75,069 shares of company stock valued at $5,102,545. Insiders own 3.20% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in EXAS. Quantbot Technologies LP acquired a new stake in shares of EXACT Sciences during the 1st quarter worth $135,000. Cornerstone Wealth Management LLC acquired a new stake in shares of EXACT Sciences during the 2nd quarter worth $182,000. Hartford Investment Management Co. acquired a new stake in shares of EXACT Sciences during the 2nd quarter worth $202,000. Fulton Bank N.A. acquired a new stake in shares of EXACT Sciences during the 3rd quarter worth $208,000. Finally, Alps Advisors Inc. acquired a new stake in EXACT Sciences in the 2nd quarter valued at $210,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Read More: Find a Trading Strategy That Works

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.